Outcome of trabeculectomy with Ologen versus Mitomycin C: A comparative prospective study in Bangladesh. Issue 2 (March 2019)

• Record Type: Journal Article
• Authors: Sarker, Bipul Kumer De; Abdullahi, Sadiq M; Hassan, Zafrul; Kabir, Jahangir; Badmus, Sarat; Alam, Sarwar; Rahman, Mostafizur; Malek, Mohammad I; Mahatma, Mallika
• Is Part Of: European journal of ophthalmology. Volume 29:Issue 2(2019)
• Page Start: 183
• Page End: 188
• Publication Date: 2019-03
• Subjects: Mitomycin C -- Ologen -- outcome -- trabeculectomy; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.1177/1120672118771841
• Languages: English
• ISSNs: 1120-6721

Abstract

Aims: To compare the efficacy and safety of trabeculectomy with Ologen versus Mitomycin C in primary glaucoma Materials and methods: This is a prospective study of patients aged 18 years and above, diagnosed with primary glaucoma randomised to having trabeculectomy with Ologen or Mitomycin C. The primary outcome measure was success of trabeculectomy defined as intraocular pressure >5 mmHg but ≤21 mmHg. Complete success was defined as intraocular pressure achieved without anti-glaucoma medication and qualified success was defined as intraocular pressure achieved with additional anti-glaucoma medication. Results: At the end of 12 months follow-up, the postoperative mean intraocular pressure in the Ologen group was 12.8 ± 1.6 mmHg and 13.4 ± 2.2 mmHg in the Mitomycin C group. The Ologen group achieved complete success in 86.5% and qualified success in 13.5% of the patients, while the Mitomycin C group achieved complete and qualified success in 85.5% and 14.5%, respectively. There was no statistically significant difference in the success rate of both the groups ( p = 0.57). Furthermore, no significant intraocular pressure difference was noted between the two groups at the end of 12 months follow-up ( p = 0.14). Conclusion: Trabeculectomy augmented with Ologen appeared to be as successful and safe as trabeculectomy augmented with Mitomycin C, with no reported adverse reaction to Ologen.